We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-22.77%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.72B
AUM Growth
-$1.36B
Cap. Flow
-$888M
Cap. Flow %
-51.56%
Top 10 Hldgs %
32.97%
Holding
299
New
73
Increased
48
Reduced
40
Closed
96

Top Buys

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$37.8M
2
GH icon
Guardant Health
GH
+$19.9M
3
LUNG icon
Pulmonx
LUNG
+$15.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.5M
5
LYRA
LYRA THERAPEUTICS INC
LYRA
+$11.2M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$18M
2
CCCC icon
C4 Therapeutics
CCCC
+$15.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13.5M
4
ICUI icon
ICU Medical
ICUI
+$12.8M
5
CNVY
Convey Health Solutions Holdings, Inc.
CNVY
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 32.95%
2 Industrials 0.3%
3 Consumer Staples 0.27%
4 Materials 0.11%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
251
CALL
Natera
NTRA
$45.5B
– –
-275,000
Closed -$11.2M
NVST icon
252
PUT
Envista
NVST
$4.61B
– –
-260,000
Closed -$12.7M
OEF icon
253
CALL
iShares S&P 100 ETF
OEF
$20.4B
– –
-100,000
Closed -$13M
PRQR icon
254
CALL
ProQR Therapeutics
PRQR
$262M
– –
-277,900
Closed -$252K
PTGX icon
255
Protagonist Therapeutics
PTGX
$9.84B
– –
-65,371
Closed -$1.55M
PTON icon
256
Peloton Interactive
PTON
$2.38B
– –
-80,000
Closed -$2.11M
PYXS icon
257
Pyxis Oncology
PYXS
$201M
– –
-113,362
Closed -$458K
QQQ icon
258
PUT
Invesco QQQ Trust
QQQ
$481B
– –
-300,000
Closed -$109M
QTRX icon
259
CALL
Quanterix
QTRX
$139M
– –
-344,600
Closed -$10.1M
RCUS icon
260
CALL
Arcus Biosciences
RCUS
$3.69B
– –
-50,000
Closed -$1.58M
RLMD icon
261
Relmada Therapeutics
RLMD
$503M
– –
-14,885
Closed -$325K
RMD icon
262
PUT
ResMed
RMD
$32.8B
– –
-57,500
Closed -$13.9M
SPY icon
263
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$809B
– –
-450,000
Closed -$203M
SRPT icon
264
Sarepta Therapeutics
SRPT
$1.94B
– –
-25,850
Closed -$1.9M
STAA icon
265
CALL
STAAR Surgical
STAA
$1.27B
– –
-85,000
Closed -$6.79M
STAA icon
266
PUT
STAAR Surgical
STAA
$1.27B
– –
-170,000
Closed -$13.6M
STXS icon
267
Stereotaxis
STXS
$139M
– –
-1,479,292
Closed -$5.52M
TDOC icon
268
PUT
Teladoc Health
TDOC
$1.22B
– –
-50,000
Closed -$3.61M
TECH icon
269
Bio-Techne
TECH
$11.3B
– –
-100,000
Closed -$10.8M
THC icon
270
CALL
Tenet Healthcare
THC
$21.5B
– –
-95,000
Closed -$8.17M
TMO icon
271
PUT
Thermo Fisher Scientific
TMO
$223B
– –
-19,000
Closed -$11.2M
TNGX icon
272
Tango Therapeutics
TNGX
$4.31B
– –
-82,727
Closed -$627K
TXG icon
273
10x Genomics
TXG
$7.52B
– –
-22,257
Closed -$1.15M
TXMD icon
274
TherapeuticsMD
TXMD
$24.1M
– –
-32,382
Closed -$615K
UHS icon
275
PUT
Universal Health Services
UHS
$10.2B
– –
-30,000
Closed -$4.35M
8 9 10
11
12

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q2 2022 Portfolio in Review

As of Q2 2022, Pura Vida Investments held 299 positions worth $1.72B, down 44% from $3.08B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Pura Vida Investments withdrew a net $888M in Q2 2022, closing 96 positions and reducing 40 holdings. Its most notable exit was C4 Therapeutics, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 24% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Pura Vida Investments opened a new position in Glaukos worth $36.2M.

  • Pura Vida Investments's largest Q2 2022 buy was Glaukos: 796,600 shares worth $36.2M.
  • Pura Vida Investments added most to Guardant Health in Q2 2022, an estimated $19.9M increase.
  • Pura Vida Investments's biggest Q2 2022 reduction was Vertex Pharmaceuticals, cutting an estimated $18M.
  • Pura Vida Investments fully exited C4 Therapeutics in Q2 2022, selling an estimated $15.2M.
  • Pura Vida Investments's ten largest holdings make up 33% of its $1.72B portfolio in Q2 2022.
  • Pura Vida Investments opened 73 new positions and closed 96 in Q2 2022.
  • Pura Vida Investments's portfolio value fell 44% quarter-over-quarter to $1.72B.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.